adriamycin + chlorambucil + fluorouracil + methotrexate + vincristine

This is a combination chemotherapy regimen consisting of five cytotoxic agents: adriamycin (doxorubicin), chlorambucil, fluorouracil (5-FU), methotrexate, and vincristine. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells through different pathways: - Adriamycin (doxorubicin) is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, leading to DNA strand breaks. - Chlorambucil is an alkylating agent that crosslinks DNA strands, preventing cell replication. - Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, disrupting DNA synthesis. - Methotrexate is an antimetabolite and antifolate agent that inhibits dihydrofolate reductase, blocking nucleotide synthesis. - Vincristine is a vinca alkaloid that binds tubulin and disrupts microtubule formation during mitosis. This multi-agent regimen aims to maximize anti-tumor efficacy by combining drugs with complementary mechanisms while minimizing overlapping toxicities. Such combinations are used in the treatment of various malignancies—most notably breast cancer—especially in advanced or refractory cases[2]. The specific combination listed here does not correspond to a widely recognized named protocol but represents an intensive polychemotherapy approach.